JP7695881B2 - 操作されたｃｄ２５ポリペプチドおよびその使用 - Google Patents

操作されたｃｄ２５ポリペプチドおよびその使用 Download PDF

Info

Publication number
JP7695881B2
JP7695881B2 JP2021526460A JP2021526460A JP7695881B2 JP 7695881 B2 JP7695881 B2 JP 7695881B2 JP 2021526460 A JP2021526460 A JP 2021526460A JP 2021526460 A JP2021526460 A JP 2021526460A JP 7695881 B2 JP7695881 B2 JP 7695881B2
Authority
JP
Japan
Prior art keywords
binding
fold
antibody
engineered polypeptide
engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021526460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513043A (ja
JPWO2020102603A5 (https=
JP2022513043A5 (https=
Inventor
ピー グリービング，マシュー
トゥ ジップ，プン
スリニバサン，モハン
モリン，アンドリュー
エドゥアルド ハウザー，ケビン
アール ウィリス，ジョーダン
エイ ムーア，コディ
バレット，クリスチャン
ティ タグチ，アレックス
エステリェス，アンヘレス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ibio Inc
Original Assignee
Ibio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ibio Inc filed Critical Ibio Inc
Publication of JP2022513043A publication Critical patent/JP2022513043A/ja
Publication of JPWO2020102603A5 publication Critical patent/JPWO2020102603A5/ja
Publication of JP2022513043A5 publication Critical patent/JP2022513043A5/ja
Priority to JP2024199831A priority Critical patent/JP2025026923A/ja
Application granted granted Critical
Publication of JP7695881B2 publication Critical patent/JP7695881B2/ja
Priority to JP2026003911A priority patent/JP2026065087A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021526460A 2018-11-14 2019-11-14 操作されたｃｄ２５ポリペプチドおよびその使用 Active JP7695881B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024199831A JP2025026923A (ja) 2018-11-14 2024-11-15 操作されたｃｄ２５ポリペプチドおよびその使用
JP2026003911A JP2026065087A (ja) 2018-11-14 2026-01-13 操作されたｃｄ２５ポリペプチドおよびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862767431P 2018-11-14 2018-11-14
US62/767,431 2018-11-14
US201962902334P 2019-09-18 2019-09-18
US62/902,334 2019-09-18
PCT/US2019/061567 WO2020102603A1 (en) 2018-11-14 2019-11-14 Engineered cd25 polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024199831A Division JP2025026923A (ja) 2018-11-14 2024-11-15 操作されたｃｄ２５ポリペプチドおよびその使用

Publications (4)

Publication Number Publication Date
JP2022513043A JP2022513043A (ja) 2022-02-07
JPWO2020102603A5 JPWO2020102603A5 (https=) 2023-06-14
JP2022513043A5 JP2022513043A5 (https=) 2023-06-14
JP7695881B2 true JP7695881B2 (ja) 2025-06-19

Family

ID=70731914

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021526460A Active JP7695881B2 (ja) 2018-11-14 2019-11-14 操作されたｃｄ２５ポリペプチドおよびその使用
JP2024199831A Pending JP2025026923A (ja) 2018-11-14 2024-11-15 操作されたｃｄ２５ポリペプチドおよびその使用
JP2026003911A Pending JP2026065087A (ja) 2018-11-14 2026-01-13 操作されたｃｄ２５ポリペプチドおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024199831A Pending JP2025026923A (ja) 2018-11-14 2024-11-15 操作されたｃｄ２５ポリペプチドおよびその使用
JP2026003911A Pending JP2026065087A (ja) 2018-11-14 2026-01-13 操作されたｃｄ２５ポリペプチドおよびその使用

Country Status (6)

Country Link
US (1) US12441803B2 (https=)
EP (1) EP3880698A4 (https=)
JP (3) JP7695881B2 (https=)
CN (1) CN113646330A (https=)
CA (1) CA3120102A1 (https=)
WO (1) WO2020102603A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
CA3120096A1 (en) 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Cd25 antibodies
EP3976083A4 (en) * 2019-05-31 2023-07-12 iBio, Inc. MACHINE LEARNING BASED DEVICE FOR THE DEVELOPMENT OF MESO-SCALE PEPTIDES, AND METHOD AND SYSTEM THEREOF
WO2021119261A1 (en) * 2019-12-10 2021-06-17 Homodeus, Inc. Generative machine learning models for predicting functional protein sequences
CN116745318A (zh) * 2020-11-10 2023-09-12 斯克里普斯研究学院 用于阿片样物质治疗的抗体
US20240096443A1 (en) * 2020-12-01 2024-03-21 Ibio, Inc. Generalized Scaffolds for Polypeptide Display and Uses Thereof
US20250179196A1 (en) * 2021-07-30 2025-06-05 Janssen Biotech, Inc. Materials and methods of making or using il-23r binding proteins
CN114384245B (zh) * 2022-03-24 2022-06-24 江苏美克医学技术有限公司 新型冠状病毒s-rbd蛋白和n蛋白双表位识别的联检试剂盒及其应用
WO2025235413A1 (en) * 2024-05-05 2025-11-13 Duke University Compositions targeting cancer antigens and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016519658A (ja) 2013-03-13 2016-07-07 アメリカ合衆国 融合前ｒｓｖｆタンパク質およびそれらの使用
JP2017528143A (ja) 2014-09-10 2017-09-28 ザ ユニバーシティ オブ コネチカット 癌の治療のための免疫防御ネオエピトープ同定
WO2018167104A1 (en) 2017-03-17 2018-09-20 Tusk Therapeutics Ltd Fc-optimized anti-cd25 for tumour specific cell depletion

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1279057C (zh) * 2002-07-12 2006-10-11 马菁 重组的抗cd25单克隆抗体、其编码序列及应用
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
CN107129524B (zh) 2007-09-25 2023-11-21 田园温室气体研究有限公司 用于抑制微生物细胞的疫苗和疫苗组分
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
WO2016179212A1 (en) 2015-05-05 2016-11-10 Albert Einstein College Of Medicine, Inc. Antibody therapeutics against filovirus infections and uses thereof
WO2018089829A1 (en) * 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
CN110856446A (zh) * 2017-04-18 2020-02-28 阿法姆海外股份有限公司 抗pd-l1抗体及其用途
JP7464530B2 (ja) * 2018-03-28 2024-04-09 ブリストル－マイヤーズ スクイブ カンパニー インターロイキン－２／インターロイキン－２受容体アルファ融合タンパク質および使用方法
CA3120096A1 (en) 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Cd25 antibodies
EP3976083A4 (en) 2019-05-31 2023-07-12 iBio, Inc. MACHINE LEARNING BASED DEVICE FOR THE DEVELOPMENT OF MESO-SCALE PEPTIDES, AND METHOD AND SYSTEM THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016519658A (ja) 2013-03-13 2016-07-07 アメリカ合衆国 融合前ｒｓｖｆタンパク質およびそれらの使用
JP2017528143A (ja) 2014-09-10 2017-09-28 ザ ユニバーシティ オブ コネチカット 癌の治療のための免疫防御ネオエピトープ同定
WO2018167104A1 (en) 2017-03-17 2018-09-20 Tusk Therapeutics Ltd Fc-optimized anti-cd25 for tumour specific cell depletion

Also Published As

Publication number Publication date
US20230016112A1 (en) 2023-01-19
WO2020102603A1 (en) 2020-05-22
JP2022513043A (ja) 2022-02-07
JP2025026923A (ja) 2025-02-26
JP2026065087A (ja) 2026-04-14
US12441803B2 (en) 2025-10-14
EP3880698A4 (en) 2022-11-30
CA3120102A1 (en) 2020-05-22
CN113646330A (zh) 2021-11-12
EP3880698A1 (en) 2021-09-22

Similar Documents

Publication Publication Date Title
JP7695881B2 (ja) 操作されたｃｄ２５ポリペプチドおよびその使用
TWI878430B (zh) 新型多肽複合物
KR20220041784A (ko) 메소 스케일 조작된 펩티드 및 선택 방법
EP2890711B1 (en) Method for producing antibody molecules having inter-species, intra-target cross-reactivity
US20040110226A1 (en) Antibody optimization
US20190023806A1 (en) Camelid hemoglobin antibodies and methods of use
JP7217772B2 (ja) 三次元構造に基づくヒト化方法
AU2015364687A1 (en) Intercalated single-chain variable fragments
CN118702814B (zh) 一种抗ngf单克隆抗体及其应用
CN113677691A (zh) 选择功能界面模拟物的方法及其组合物
HK40063514A (en) Engineered cd25 polypeptides and uses thereof
JP2024523921A (ja) 特異的バインダーの選択手段及び方法
CN101426526B (zh) 使用工程诱杀蛋白的液相生物淘选方法
Chen et al. Improved isolation of anti-rhTNF-α scFvs from phage display library by bioinformatics
CN117836308A (zh) 用于选择特异性结合剂的手段和方法
WO2025258355A1 (ja) 抗体ライブラリ、遺伝子ライブラリ、抗体ライブラリの製造方法および抗原認識方法
HK40098558A (zh) 基於三维结构的人源化方法
WO2022037527A1 (zh) 结合bcma的单可变结构域及抗原结合分子
HK40076302B (zh) 新型多肽复合物
Pszolla Computational design of novel interactions in conventional and heavy chain antibodies
HK40023878B (zh) 基於三维结构的人源化方法
HK1132177B (en) Solution phase biopanning method using engineered decoy proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221111

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20221111

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20221129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230421

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20221111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240424

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241115

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250314

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250519

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250609

R150 Certificate of patent or registration of utility model

Ref document number: 7695881

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150